Figure S7.
PC4 exhibits distinct modifications in HCC, and PC4 loss sensitizes HCC cells to CDK4/6 inhibitors. Related to Fig. 7. (A) Western blot showing the phosphorylated and unphosphorylated PC4 expressions in four liver cells (Huh7, HepG2, L-02, and LX-2). (B) Western blot showing ubiquitination and phosphorylation levels of endogenous PC4 in four liver cells (Huh7, HepG2, L-02, and LX-2). (C) Body weight from CLANNC(n = 6), Palbociclib (n = 6), CLANsiPC4(n = 6), or Palbociclib+CLANsiPC4 (n = 6) -treated Huh7-Luc xenografts mice at each time point in Fig. 7 F. (D) Luminescence value from Huh7-Luc xenografts mice treated in Fig. 7 G. Data were generated from n = 6 in each group. (E) Quantification of tumor weight from Huh7-Luc xenografts mice treated in Fig. 7 F. Data were generated from n = 6 in each group. (F) Quantification of metastatic luminescence value in Fig. 7 L. Data are generated from n = 6 in each group. (G) Quantification of metastatic area in Fig. 7 L. Data are generated from n = 6 in each group. (H) Western blot showing the indicated protein expressions in CLANNC (n = 3), Palbociclib (n = 3), CLANsiPC4 (n = 3), and Palbociclib+CLANsiPC4 (n = 3) -treated Huh7-Luc xenografts. (I) Quantifications of CCND1 intensity in immunostaining from Huh7-Luc xenografts mice treated in Fig. 7 F. (J) Quantifications of p-CDK2 intensity in immunostaining from Huh7-Luc xenografts mice treated in Fig. 7 F. (K) Quantifications of p-RB intensity in immunostaining from Huh7-Luc xenografts mice treated in Fig. 7 F. (L) Quantifications of PC4 intensity in immunostaining from Huh7-Luc xenografts mice treated in Fig. 7 F. All quantifications were shown as means ± SD (one-way ANOVA test); error bars represent SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. A, B, H, and J–L are independent experiments. Source data are available for this figure: SourceData FS7.

PC4 exhibits distinct modifications in HCC, and PC4 loss sensitizes HCC cells to CDK4/6 inhibitors. Related to Fig. 7. (A) Western blot showing the phosphorylated and unphosphorylated PC4 expressions in four liver cells (Huh7, HepG2, L-02, and LX-2). (B) Western blot showing ubiquitination and phosphorylation levels of endogenous PC4 in four liver cells (Huh7, HepG2, L-02, and LX-2). (C) Body weight from CLANNC(n = 6), Palbociclib (n = 6), CLANsiPC4(n = 6), or Palbociclib+CLANsiPC4 (n = 6) -treated Huh7-Luc xenografts mice at each time point in Fig. 7 F. (D) Luminescence value from Huh7-Luc xenografts mice treated in Fig. 7 G. Data were generated from n = 6 in each group. (E) Quantification of tumor weight from Huh7-Luc xenografts mice treated in Fig. 7 F. Data were generated from n = 6 in each group. (F) Quantification of metastatic luminescence value in Fig. 7 L. Data are generated from n = 6 in each group. (G) Quantification of metastatic area in Fig. 7 L. Data are generated from n = 6 in each group. (H) Western blot showing the indicated protein expressions in CLANNC (n = 3), Palbociclib (n = 3), CLANsiPC4 (n = 3), and Palbociclib+CLANsiPC4 (n = 3) -treated Huh7-Luc xenografts. (I) Quantifications of CCND1 intensity in immunostaining from Huh7-Luc xenografts mice treated in Fig. 7 F. (J) Quantifications of p-CDK2 intensity in immunostaining from Huh7-Luc xenografts mice treated in Fig. 7 F. (K) Quantifications of p-RB intensity in immunostaining from Huh7-Luc xenografts mice treated in Fig. 7 F. (L) Quantifications of PC4 intensity in immunostaining from Huh7-Luc xenografts mice treated in Fig. 7 F. All quantifications were shown as means ± SD (one-way ANOVA test); error bars represent SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. A, B, H, and J–L are independent experiments. Source data are available for this figure: SourceData FS7.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal